NEW YORK (GenomeWeb) – BioMérieux is collaborating with Bioaster, a French accelerator of microbiology technology innovation; ESPCI, the College of Physics and Industrial Chemistry of the city of Paris; GSK; HCL, the Hospices Civils de Lyon; and Sanofi to identify and validate new biomarkers aimed at diagnosing patients that present with high risk of sepsis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.